Abstract
The coplanar 3,3',4,4'-tetrachlorobiphenyl (TCB) was given orally to mice and the metabolite patterns in feces, urine, liver, and adipose tissue were examined. In feces, 80% of the dose was excreted within 5 days. 5-Hydroxy-, 6-hydroxy-TCB, 4-hydroxy-3,3',4',5-tetrachlorobiphenyl, and unmetabolized TCB were identified by comparison to synthetic standards (GC/MS). 4-Hydroxy-trichlorobiphenyl and a dihydroxy-trichlorobiphenyl were indicated by the fragmentation pattern of the corresponding methylated derivatives by GC/MS. In urine, 4.9% of the TCB dose was excreted mainly as conjugates. After hydrolysis, TCB and seven hydroxylated metabolites were detected; 2-, 5-, and 6-hydroxy-TCB and 4-hydroxy-3,3',4',5-tetrachlorobiphenyl were identified and two dihydroxy-tetrachlorobiphenyls were indicated. The major compound detected after hydrolysis of urine was a dihydroxy-trichlorobiphenyl. TCB was the major compound present in the liver, while a minor portion was due to 4-hydroxy-3,3',4',5-tetrachlorobiphenyl. TCB, 4-hydroxy-3,3',4',5-tetrachlorobiphenyl, and 5- and 6-hydroxy-TCB were present in adipose tissue. In addition, radiolabeled material was present in a lipid fraction obtained after gel permeation chromatography of all samples except urine, indicating the presence of TCB metabolites with lipid characteristics.
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|